Navigation Links
Penicillin equally effective as 'big gun' antibiotics for treating less severe childhood pneumonia
Date:12/9/2013

Children hospitalized for pneumonia have similar outcomes, including length of stay and costs, regardless of whether they are treated with "big gun" antibiotics such as ceftriaxone or cefotaxime or more narrowly focused antibiotics such as ampicillin or penicillin, according to a Vanderbilt study published in Pediatrics.

Study authors said the findings are important because pneumonia is one of the most common reasons for hospitalization among U.S. children and because broad-spectrum antibiotics are frequently overprescribed, leading to antibiotic resistance.

"Sometimes there is a perception, not restricted to pneumonia, that the use of a broad spectrum antibiotic, a big gun, is going to be the best treatment for all patients. This perception can complicate the selection of antibiotics especially when there is limited information to support the decision," said senior author Carlos G. Grijalva, M.D., MPH, assistant professor of Health Policy. "To help inform those decisions, this study compared two pneumonia treatment regimens, a big gun (broad spectrum antibiotics) vs. a small gun (narrow spectrum antibiotics), and found there were no significant differences in clinical outcomes or associated costs."

In Summer 2011, the Pediatric Infectious Diseases Society and Infectious Diseases Society of America (PIDS/IDSA) released joint community-acquired pneumonia guidelines that recommend narrow-spectrum antibiotic therapy for most children hospitalized with pneumonia but, until now, few studies had compared the effectiveness of this strategy relative to use of broad spectrum antibiotics.

Using data from 43 children's hospitals in the U.S., the authors compared outcomes among children 6 months to 18 years of age hospitalized for pneumonia between 2005 and 2011, receiving either ampicillin or penicillin (narrow spectrum) or a third generation cephalosporin (ceftriaxone or cefotaxime,[broad spectrum]). According to the PIDS/IDSA guidelines, both treatment strategies are effective for disease caused by Streptococcus pneumoniae, the most common bacterial cause of pneumonia.

Lead author Derek J. Williams, M.D. MPH, assistant professor of Pediatrics, said doctors worry about increases in unnecessary use of broad spectrum antibiotics because they drive increases in disease caused by antibiotic-resistant bacteria.

"We have seen increases in use of broad spectrum antibiotics and concurrent increases in disease caused by resistant bacteria. For this study, we hypothesized that narrow and broad-spectrum antibiotics would have similar effectiveness in the treatment of childhood pneumonia. Our findings support the preferential use of narrow spectrum antibiotics as first-line therapies for most children hospitalized with pneumonia," Williams said.

"Although interventions such as the introduction of the pneumococcal conjugate vaccines into the U.S. childhood vaccination schedule in 2000 have led to reductions in pneumococcal disease in general and reductions in disease caused by vaccine strains resistant to antibiotics, additional actions are necessary to inform antibiotic selection and to continue reducing antibiotic resistance."

In the study, nearly 90 percent of children received broad-spectrum therapy, compared with only 10 percent receiving narrow-spectrum therapy.

"The 2011 PIDS/IDSA guidelines recommending ampicillin or penicillin represents a major shift toward more narrowly focused treatment, and this is one of the first studies that directly compared these agents against the more commonly used broader spectrum therapies," Williams said. "Although ampicillin or penicillin therapy was as effective as the third generation cephalosporins, use of the narrower spectrum drugs was very uncommon prior to release of the guidelines. In the near future, it would be interesting to evaluate whether the release of the consensus guidelines and related efforts facilitate widespread adoption of the new treatment recommendations."


'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Penicillin Prevents Return of Leg Infection Called Cellulitis: Study
2. Economic analysis finds penicillin, not "the pill," may have launched the sexual revolution
3. Study finds mechanical chest compressions are equally as effective as manual CPR
4. Not all patients benefit equally from hip or knee replacement: Study finds
5. Bypass Patients Fare Equally Well With or Without Heart-Lung Machine
6. Gene Disorder Screen Benefits Baby Boys, Girls Equally: Study
7. Constipation Treatments Not Equally Effective: Review
8. Not all stem cells are equally efficient for use in regenerative medicine
9. Obesity epidemic threatens health of all social groups equally
10. 2 Common Blood Pressure Meds Fare Equally in Preventing Heart Woes
11. Recycled plastic proves effective in killing drug-resistant fungi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... City trips ... (IBT World Travel Trends Report). As travelers visit both urban destinations, they are ... and prolonged sun exposure. In response, the outdoor industry has blurred the lines ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon and well-known ... to offer the recently FDA-approved Obalon Balloon System to his patients. The Obalon ... Surgical’s already comprehensive list of weight-loss services. Dr. Liu is proud to ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017  Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. ... of directors: Christopher Gabrieli ... serve as chairman of the board of Akcea Therapeutics. ... of Forest Laboratories. Sandford D. Smith ... "We are excited to announce this expansion to ...
(Date:3/28/2017)... , March 28, 2017 ... expected to reach a value of USD 4.5 billion ... View Research, Inc. Proper closure of injured tissues post ... and function. Postoperative leakages occur in 3% to 15% ... They are responsible for one third of postoperative deaths ...
(Date:3/27/2017)... , March 27, 2017 The National ... health and data analytics company, signed a Memorandum ... improving healthcare delivery in the region. ... Global Health Research and Technology (BIGHEART) at NUS ... several topics related to healthcare IT and medical ...
Breaking Medicine Technology: